Gemfibrozil Tablet
Product Images NDC 68071-1733

6 FDA label images from Nucare Pharmaceuticals,inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 68071-1733). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (B1f01502 634b 461a 8985 B639d190c9ef 01)

Image (B1f01502 634b 461a 8985 B639d190c9ef 01)
Chemical structure of gemfibrozil, showing its molecular arrangement with labeled atoms and bonds typical of the compound used as an oral tablet for prescription use.*
FDA Label Image

Image (B1f01502 634b 461a 8985 B639d190c9ef 02)

Image (B1f01502 634b 461a 8985 B639d190c9ef 02)
A data table titled 'Reduction in CHD Rates (events per 1000 patients) by Baseline Lipids in the Helsinki Heart Study, Years 0-5' comparing incidence of cardiovascular events between placebo and gemfibrozil tablet groups. The table shows event rates and differences across various lipid baseline categories for all patients and subgroups defined by LDL cholesterol, HDL cholesterol, and triglyceride levels.*
FDA Label Image

Image (B1f01502 634b 461a 8985 B639d190c9ef 03)

Image (B1f01502 634b 461a 8985 B639d190c9ef 03)
A data table titled 'Cardiac Events and All-Cause Mortality (events per 1000 patients) Occurring During the 3.5 Year Open-Label Follow-up to the Helsinki Heart Study.' It presents event rates for six groups differentiated by original randomization and follow-up drug status, including placebo and gemfibrozil tablets, with group sizes and corresponding rates of cardiac events and all-cause mortality per 1000 patients.*
FDA Label Image

Image (B1f01502 634b 461a 8985 B639d190c9ef 04)

Image (B1f01502 634b 461a 8985 B639d190c9ef 04)
A data table titled 'Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths and All-Cause Mortality in the Helsinki Heart Study, Years 0-8.5' comparing Gemfibrozil and placebo groups. It presents counts of cardiac events and deaths, hazard ratios for Gemfibrozil versus placebo, and 95% confidence intervals for hazard ratios.*
FDA Label Image

Image (B1f01502 634b 461a 8985 B639d190c9ef 05)

Image (B1f01502 634b 461a 8985 B639d190c9ef 05)
A data table listing adverse reactions categorized by system organ class for Gemfibrozil. It separates reactions into 'causal relationship probable' and 'causal relationship not established,' covering gastrointestinal, central nervous system, musculoskeletal, immunologic, hematopoietic, clinical laboratory, and other systems.*
FDA Label Image

Pdp (68071 1733 6)

Pdp (68071 1733 6)
Label for Gemfibrozil 600 mg tablets by NuCare Pharmaceuticals, Inc. The oral tablet package contains 60 tablets. The label includes NDC 68071-1733-6, product number R0268060, and states Rx Only. It warns to keep out of reach of children and to store at controlled temperature 68-77°F. Manufacturer is InvaGen Pharmaceuticals Inc., Hauppauge, NY.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.